Bibliographic Details
| Title: |
Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era. |
| Authors: |
Wensink, G. Emerens, Elferink, Marloes A. G., May, Anne M., Mol, Linda, Hamers, Patricia A. H., Bakker, Sandra D., Creemers, Geert-Jan, de Groot, Jan Willem B., de Klerk, Gerty J., Haberkorn, Brigitte C. M., Haringhuizen, Annebeth W., Hoekstra, Ronald, Hunting, J. Cornelis B., Kerver, Emile D., Mathijssen-van Stein, Danielle, Polée, Marco B., Pruijt, Johannes F. M., Quarles van Ufford-Mannesse, Patricia, Radema, Sandra, Rietbroek, Ronald C. |
| Source: |
British Journal of Cancer; 2021, Vol. 124 Issue 2, p399-406, 8p |
| Abstract: |
Background: Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy.Methods: Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials; n = 227 from the Netherlands Cancer Registry). Overall survival was analysed from diagnosis of mCRC (OS), from initiation of first-line (OS1) and second-line (OS2) systemic treatment. Cox regression analysis examined prognostic factors. As comparison for OS 2746 MMR proficient mCRC patients were identified.Results: Of 281 dMMR patients, 62% received first-line and 26% second-line treatment. Median OS was 16.0 months (13.8-19.6) with antitumour therapy and 2.5 months (1.8-3.5) in untreated patients. OS1 was 12.8 months (10.7-15.2) and OS2 6.2 months (5.4-8.9) in treated dMMR patients. Treated dMMR patients had a 7.6-month shorter median OS than pMMR patients.Conclusion: Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Cancer is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
